tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Tongue Diseases D014060 2 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Nail Diseases D009260 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Skin Diseases, Papulosquamous D017444 2 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Neuroaspergillosis D020953 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Venous Insufficiency D014689 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Telangiectasis D013684 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Vitiligo D014820 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Eye Infections, Fungal D015821 2 associated lipids
Tumor Lysis Syndrome D015275 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Cholecystolithiasis D041761 2 associated lipids
Brachial Plexus Neuritis D020968 2 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Pruritus Ani D011538 2 associated lipids
Deglutition Disorders D003680 2 associated lipids
Discitis D015299 2 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Collagen Diseases D003095 2 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
DuBell WH et al. K(+) currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. 2000 Am. J. Physiol. Heart Circ. Physiol. pmid:10710358
Balasubramaniam R et al. Caffeine-induced arrhythmias in murine hearts parallel changes in cellular Ca(2+) homeostasis. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:15923307
Hafizi S et al. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. 2004 Am. J. Physiol. Heart Circ. Physiol. pmid:15317677
Giordano A et al. Rapamycin antagonizes NF-kappaB nuclear translocation activated by TNF-alpha in primary vascular smooth muscle cells and enhances apoptosis. 2006 Am. J. Physiol. Heart Circ. Physiol. pmid:16428340
Kohno M et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. 2003 Am. J. Physiol. Heart Circ. Physiol. pmid:12433661
Sasamori K et al. Cyclic ADP-ribose, a putative Ca2+-mobilizing second messenger, operates in submucosal gland acinar cells. 2004 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:14990397
Lum H et al. Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction. 2001 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:11504680
Yaghi A and Sims SM Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. 2005 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:16055480
Bouvier N et al. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. 2009 Am. J. Physiol. Renal Physiol. pmid:18987109
Ren H et al. Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane. 2016 Am. J. Physiol. Renal Physiol. pmid:27488997
Thai TL et al. ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo. 2007 Am. J. Physiol. Renal Physiol. pmid:17652368
Peherstorfer E et al. Effects of microinjection of synthetic Bcl-2 domain peptides on apoptosis of renal tubular epithelial cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12060601
Axelsson J et al. Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. 2013 Am. J. Physiol. Renal Physiol. pmid:23657856
Mohebbi N et al. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. 2009 Am. J. Physiol. Renal Physiol. pmid:19439519
Cho SG et al. Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. 2010 Am. J. Physiol. Renal Physiol. pmid:20410216
De Miguel C et al. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. 2011 Am. J. Physiol. Renal Physiol. pmid:21159736
Rojas-Vega L et al. Increased phosphorylation of the renal Na+-Cl- cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort. 2015 Am. J. Physiol. Renal Physiol. pmid:26336164
Edinger RS et al. Effect of immunosuppressive agents on glucocorticoid receptor function in A6 cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12110508
Ilori TO et al. Acute calcineurin inhibition with tacrolimus increases phosphorylated UT-A1. 2012 Am. J. Physiol. Renal Physiol. pmid:22205230
Amberg GC et al. Regulation of A-type potassium channels in murine colonic myocytes by phosphatase activity. 2001 Am. J. Physiol., Cell Physiol. pmid:11698261
Ahn HS et al. Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. 2007 Am. J. Physiol., Cell Physiol. pmid:17166943
Wang YX et al. FKBP12.6 and cADPR regulation of Ca2+ release in smooth muscle cells. 2004 Am. J. Physiol., Cell Physiol. pmid:14592808
Sans MD and Williams JA Calcineurin is required for translational control of protein synthesis in rat pancreatic acini. 2004 Am. J. Physiol., Cell Physiol. pmid:15044154
Bayguinov O et al. Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes. 2001 Am. J. Physiol., Cell Physiol. pmid:11171588
Angus LM et al. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. 2005 Am. J. Physiol., Cell Physiol. pmid:15930144
Zhang Y et al. K restriction inhibits protein phosphatase 2B (PP2B) and suppression of PP2B decreases ROMK channel activity in the CCD. 2008 Am. J. Physiol., Cell Physiol. pmid:18184875
Yue G et al. The effect of rapamycin on single ENaC channel activity and phosphorylation in A6 cells. 2000 Am. J. Physiol., Cell Physiol. pmid:10898719
Nam JH et al. Expression of TASK-2 and its upregulation by B cell receptor stimulation in WEHI-231 mouse immature B cells. 2011 Am. J. Physiol., Cell Physiol. pmid:21307343
Nakagawa K et al. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. 2015 Am. J. Reprod. Immunol. pmid:25394810
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Saito S et al. Role of Paternal Antigen-Specific Treg Cells in Successful Implantation. 2016 Am. J. Reprod. Immunol. pmid:26706630
Kofod L et al. Endometrial immune markers are potential predictors of normal fertility and pregnancy after in vitro fertilization. 2017 Am. J. Reprod. Immunol. pmid:28440588
Tabata C et al. Calcineurin/NFAT pathway: a novel regulator of parturition. 2009 Am. J. Reprod. Immunol. pmid:19527231
Goldthorpe H et al. Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice. 2015 Am. J. Respir. Cell Mol. Biol. pmid:25879383
Fujiki M et al. Role of T cells in bronchoalveolar space in the development of interstitial pneumonia induced by superantigen in autoimmune-prone mice. 1999 Am. J. Respir. Cell Mol. Biol. pmid:10572064
Deuse T et al. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. 2010 Am. J. Respir. Cell Mol. Biol. pmid:19880819
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
Yerkovich ST et al. Survival after bronchiolitis obliterans syndrome. 2011 Am. J. Respir. Crit. Care Med. pmid:21325085
Bhorade S et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. 2011 Am. J. Respir. Crit. Care Med. pmid:20833822
Koshika T et al. Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury. 2001 Am. J. Respir. Crit. Care Med. pmid:11208629
Saeki K et al. Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient. 2017 Am. J. Respir. Crit. Care Med. pmid:28199133
Joshi MS et al. Calcineurin regulates myocardial function during acute endotoxemia. 2006 Am. J. Respir. Crit. Care Med. pmid:16424445
Fauvel H et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. 2002 Am. J. Respir. Crit. Care Med. pmid:11850335
Spiekerkoetter E et al. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. 2015 Am. J. Respir. Crit. Care Med. pmid:26177174
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Tanaka K et al. Living related liver transplantation in children. 1994 Am. J. Surg. pmid:7517649
Li X et al. Increased iNOS-expressing macrophage in long-term surviving rat small-bowel grafts. 2007 Am. J. Surg. pmid:17618815
Rabkin JM et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. 2002 Am. J. Surg. pmid:12034401
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Finn L et al. Epstein-Barr virus infections in children after transplantation of the small intestine. 1998 Am. J. Surg. Pathol. pmid:9500771
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Minervini MI et al. Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). 2000 Am. J. Surg. Pathol. pmid:10757402
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Schnitzler M Diabetes mellitus after kidney transplantation in the United States. 2003 Am. J. Transplant. pmid:14510709
Donners MM et al. Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. 2005 Am. J. Transplant. pmid:15888024
Lemahieu W et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. 2005 Am. J. Transplant. pmid:15888045
Axelrod D et al. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. 2005 Am. J. Transplant. pmid:15888050
Djamali A et al. Nox2 is a mediator of chronic CsA nephrotoxicity. 2012 Am. J. Transplant. pmid:22568654
Campbell PM et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. 2007 Am. J. Transplant. pmid:17456201
English RF et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. 2002 Am. J. Transplant. pmid:12243498
Ricciardelli I et al. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. 2013 Am. J. Transplant. pmid:24266973
McKenna G and Trotter JF Does early (CNI) conversion lead to eternal (renal) salvation? 2010 Am. J. Transplant. pmid:20928938
Hanto DW et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. 2010 Am. J. Transplant. pmid:20977633
Schold JD The burden of proof in the design of early phase clinical trials. 2013 Am. J. Transplant. pmid:23802723
Willicombe M et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. 2011 Am. J. Transplant. pmid:21299828
Kasahara M et al. Living-donor liver transplantation for hepatoblastoma. 2005 Am. J. Transplant. pmid:16095502
Lemahieu WP et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. 2005 Am. J. Transplant. pmid:16095503
Meier-Kriesche HU et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. 2005 Am. J. Transplant. pmid:16095509
Senior PA et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. 2005 Am. J. Transplant. pmid:16095517
Rodríguez-Perálvarez M et al. Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. 2013 Am. J. Transplant. pmid:23621166
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. 2002 Am. J. Transplant. pmid:12095048
Vanhove T et al. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. 2017 Am. J. Transplant. pmid:28224698
Vongwiwatana A et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. 2004 Am. J. Transplant. pmid:14678043
Filler G et al. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. 2005 Am. J. Transplant. pmid:15996252
Awadalla Y et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. 2004 Am. J. Transplant. pmid:15367226
Froud T et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. 2005 Am. J. Transplant. pmid:15996257
Borrows R et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. 2006 Am. J. Transplant. pmid:16433766
Shihab F et al. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. 2017 Am. J. Transplant. pmid:28141897
O'Connell PJ et al. Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. 2013 Am. J. Transplant. pmid:23668890
Russ GR et al. Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. 2013 Am. J. Transplant. pmid:23668931
Rodríguez-Perálvarez M et al. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. 2012 Am. J. Transplant. pmid:22703529
Guirado L et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. 2011 Am. J. Transplant. pmid:21668633
Flechner SM et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. 2011 Am. J. Transplant. pmid:21668635
Budde K How to use mTOR inhibitors? The search goes on. 2011 Am. J. Transplant. pmid:21668636
Chen G et al. Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. 2007 Am. J. Transplant. pmid:17227555
Senior PA et al. Changes in renal function after clinical islet transplantation: four-year observational study. 2007 Am. J. Transplant. pmid:17227560
Levi Z et al. Switching from tacrolimus to sirolimus halts the appearance of new sebaceous neoplasms in Muir-Torre syndrome. 2007 Am. J. Transplant. pmid:17229076
Asberg A et al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. 2010 Am. J. Transplant. pmid:20486914
Hautz T et al. Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. 2010 Am. J. Transplant. pmid:20353468
Zheng H et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. 2003 Am. J. Transplant. pmid:12694072
Montgomery SP et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 2002 Am. J. Transplant. pmid:12118862
Ahsan N et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. 2002 Am. J. Transplant. pmid:12118902
Nijhoff MF et al. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. 2016 Am. J. Transplant. pmid:26288226
Lefaucheur C et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. 2008 Am. J. Transplant. pmid:18671673
McDonald RA et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. 2008 Am. J. Transplant. pmid:18416737
Triñanes J et al. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. 2017 Am. J. Transplant. pmid:28432716
Pallet N et al. Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. 2016 Am. J. Transplant. pmid:26990694
Rogers J et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. 2003 Am. J. Transplant. pmid:14510702
Chhabra D et al. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. 2013 Am. J. Transplant. pmid:24007570